Cellerix is a biopharmaceutical company that develops innovative medicinal products based on cell therapy, using mainly expanded adult stem cells derived from adipose tissue (eASCs).
The main objective of the company is to develop standardized drugs for the treatment of highly prevalent autoimmune diseases.
Cellerix has a wide platform of candidates and products under clinical development for different indications which is supported by its proven experience at both regulatory and clinical levels (the first product developed by Cellerix was approved for Phase III studies in 8 European countries).
In 2007, Cellerix became the first European cell therapy company to license a product to a pharmaceutical company for the North American market through a license agreement signed with Axcan Pharma.